Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clin... (nt projects the efficacy of REOLYSIN as ...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> BIOLOGY >> TECHNOLOGY

Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial

Date:4/7/2009

nt projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable law.

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference

Post Your Comments:

(Date:11/6/2009)...wswire-FirstCall/ - Microbix Biosystems Inc. (the ...e Form 52-109F1 Certification of Annual Filings of...ames Long, the Chief Financial Officer (the "Offic...ection with the annual audited financial statement... Company initially filed the annual financial stat...

(Date:11/6/2009)...v. 6 ,, 3Q09 Corpo...tenza(TM) E.U. Marketing Authorization to Astellas... commercial readiness activities Expanded managem...keting; and Director, Commercial Operations Appoi...Audit Committee chairman , Upcoming 2009 Mi...

(Date:11/5/2009)... hybrid . . . , Fuel economy ratings for the n...he www.fueleconomy.gov web site, which Oak Ridge...he U.S. Department of Energy and the U.S. Environm...es on the best fuel economy list are hybrid electr...way). "This list proves that hybrids have gone mai...

(Date:11/5/2009)...., Nov. 5 ThermoGenesis ...vative products for processing and storing adult s...arter of fiscal 2010. ,, For the quarter ended ...of $5.2 million, a 15 percent increase over revenu.... The Company said the key contributors to the gro...

Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2 NeurogesX Reports Third Quarter 2009 Results 3 NeurogesX Reports Third Quarter 2009 Results 4 NeurogesX Reports Third Quarter 2009 Results 5 NeurogesX Reports Third Quarter 2009 Results 6 NeurogesX Reports Third Quarter 2009 Results 7 NeurogesX Reports Third Quarter 2009 Results 8 NeurogesX Reports Third Quarter 2009 Results 9 NeurogesX Reports Third Quarter 2009 Results 10 November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2 November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3 ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2 ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3 ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4 ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5 ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6 ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7 ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8

[1] Microbix Biosystems Re-files Annual Results With OSC [0] NeurogesX Reports Third Quarter 2009 Results [0] November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory [0] ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line

... (NYSE: WYE ),confirmed today that it will appeal...th, in the U.S. District Court, Eastern District o...There is no basis in fact or law for this award or...l pursue several post-trial motions and,will ultim...confident in,our position on appeal," says Lyn P. ...

...hway Medical Technologies,which is developing inno...al disease, announced that Paul Buckman has been n.... He replaces Dan Galles, who has been,acting Boar... Paul has accepted the role of Chairman. He brings...Pathway board, including,early commercialization e...

...nt of Chemistry Testing Market, FULLERTON, Calif....unced today that it has launched the UniCel DxC 88...rated work cell which,consolidates chemistry and i...ories. The latest addition to the company,s work c...ng chemistry system, the UniCel DxC,800, and the i...

Other Biology Technology:Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts 2 Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts 3 Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors 2 Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell 2

Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts Pathway Medical Technologies Names Paul Buckman Chairman of the Board of Directors Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell

(Date:11/6/2009)...ovember 06, 2009) The Monell Center and the Chine...eijing International Meeting on Taste and Smell Re...the CAS, the meeting will be the first internation... , Alan Leshner, Chief Executive Officer, Americ...Executive Publisher of Science magazine, will open...

(Date:11/5/2009)....Researchers at Yale University have developed syn...mmune response to HIV and HIV-infected cells, as w...ublished online in the Journal of the American Ch...pproaches for these diseases. , The molecules ..." (ARM-H) and "antibody-recruiting molecule target...

(Date:11/4/2009)...lthough scientists are reluctant to officially end...ence continues to grow about its protective effect...Cancer Prevention Research , a journal of the Amer...ts some reduction in oral cancer. , Vassiliki P...the Department of Thoracic/Head and Neck Medical O...

Breaking Biology News(10 mins):Monell Center joins with CAS to host Beijing meeting on taste and smell research 2 New synthetic molecules trigger immune response to HIV and prostate cancer 2 Does green tea prevent cancer? Evidence continues to brew, but questions remain 2 Marathon Health Expands Midwest Presence 53929 1 Marathon Health Expands Midwest Presence 53929 2 X4 Labs to Create Solid Gold Male Enhancement Device for Rich Saudi Man 53926 1 X4 Labs to Create Solid Gold Male Enhancement Device for Rich Saudi Man 53926 2 Bladder cells feel stretch 9511 1

[0] Monell Center joins with CAS to host Beijing meeting on taste and smell research [1] New synthetic molecules trigger immune response to HIV and prostate cancer [2] Does green tea prevent cancer? Evidence continues to brew, but questions remain

... local farm products were the focus of a just-comp...urce on selected Ontario farms. This province-wide... It involved six farms to evaluate the effectiven...roject was designed to accelerate the adoption of ... on-farm evaluations," said Deanna Deaville, Speci...

...ar imaging to "see" programmed cell loss—the body,...l cells—may help in early identification of those ...ilure, say researchers in the April Journal of Nuc...easible to noninvasively identify cell loss—or apo...imaging," explained Leo Hofstra, director of cardi...

...play a comparable pattern of neural activity when ...e Max Planck Institute for Dynamics and Self-Organ...ical method to design networks from neural cells w...searchers hope that their method will assist them ...ssible network configurations was privileged by ev...

Other Biology News:Biodiesel study targets cleaner air, cleaner engines 2 Heart failure: Intervention possibilities from imaging programmed cell loss 2 2 brains -- 1 thought 2 2 brains -- 1 thought 3

Biodiesel study targets cleaner air, cleaner engines Heart failure: Intervention possibilities from imaging programmed cell loss 2 brains -- 1 thought

...n Blot Strong Antibody Stripping Solution is effec...that have been developed with chemiluminescence or...ecommended for stripping colorimetric substrates (...sible to effectively remove substrates that precip...

Hybrid Hunter Yeast Two-Hybrid System from Invitrogen

Helios Gene Gun Low-Pressure System, 100-120 V from Bio-Rad

Anti-Transglutaminase II Monoclonal Antibody, Unconjugated, Clone CUB7402 from Diagnostic BioSystems

Biology Products:

ReBlot Plus Strong Antibody Stripping Solution from CHEMICON Hybrid Hunter Yeast Two-Hybrid System from Invitrogen Helios Gene Gun Low-Pressure System, 100-120 V from Bio-Rad Anti-Transglutaminase II Monoclonal Antibody, Unconjugated, Clone CUB7402 from Diagnostic BioSystems

Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clin...(nt projects the efficacy of REOLYSIN as ...)